Intra-Cellular Therapies, Inc.
ITCI
Pozycja w akcjach
#1685
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Cena akcji
$131.87
Ostatnia synchronizacja: 2025-04-02
Kapitalizacja rynkowa
$12.68B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategoria
Healthcare
Historia ceny akcji dla Intra-Cellular Therapies, Inc. (ITCI)
Najwyższa cena zamknięcia: $131.87 dnia 2025-04-01
Najniższa cena zamknięcia: $18.58 dnia 2014-01-01
Najniższa cena zamknięcia: $18.58 dnia 2014-01-01
Historia cen akcji firmy Intra-Cellular Therapies, Inc. od 2014 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2025 | 55.77% |
| 2024 | 28.97% |
| 2023 | 25.44% |
| 2022 | 22.29% |
| 2021 | 54.57% |
| 2020 | 49.37% |
| 2019 | 44.08% |
| 2018 | -15.24% |
| 2017 | -2.14% |
| 2016 | -71.45% |
| 2015 | 222.13% |
| 2014 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.15 | 20.52% |
DE
|
|
| $40.38 | 42.84% |
JP
|
|
| $212.49 | 24.09% |
CH
|
|
| $19.19 | -0.09% |
IN
|
